RayzeBio which is developing a drug that targets the same tumors as Lutathera wants to break in on the emerging market. The most richly funded of more than a dozen radiopharmaceutical startups  the company began a Phase 3 trial for its experimental neuroendocrine tumor drug RYZ101 in May